LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, ...

Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the drug developer's shares up nearly 42%, as it aims to win approval for the ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

Research will take place in the UK, including at the newly opened Centre for Mental Health Research and Innovation in London, developed in partnership with South London and Maudsley NHS Foundation ...

This open-label study included 19 patients from clinical sites in Ireland and the United States. The majority of patients were female (68.4%) and the average age was 42 years. The primary endpoint was ...

LONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...

Shares of Compass Pathways PLC climbed on Friday after the U.S.-listed healthcare group announced a successful follow-up study of a psychedelic drug used to treat major depression in cancer patients.

COMPASS Pathways' CMPS Phase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant Depression (TRD) is still nourishing the psychedelics research field, as ...

LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...